Highlights

Prolor Biotech Downgraded by Summer Street (PBTH)

 Source: ABMN Staff   |   Publish date: Mon, 12 Nov 2012, 11:58 AM   |    >> Read article in News website

Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.

Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.

Share this

  Be the first to like this.
 


 

4459  2643  565  656 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 BAC 24.215+0.585 
 JNUG 4.368-0.882 
 BABY 40.85+0.25 
 AKS 6.49-0.63 
 NUGT 8.06-1.30 
 SPY 238.79+1.62 
 GDX 22.115-1.085 
 ABX 17.083-1.957 
 FCX 12.915+0.685 
 XLF 23.965+0.285 
Partners & Brokers